Nature Communications (Nov 2021)

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

  • Brian D. Lehmann,
  • Antonio Colaprico,
  • Tiago C. Silva,
  • Jianjiao Chen,
  • Hanbing An,
  • Yuguang Ban,
  • Hanchen Huang,
  • Lily Wang,
  • Jamaal L. James,
  • Justin M. Balko,
  • Paula I. Gonzalez-Ericsson,
  • Melinda E. Sanders,
  • Bing Zhang,
  • Jennifer A. Pietenpol,
  • X. Steven Chen

DOI
https://doi.org/10.1038/s41467-021-26502-6
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 18

Abstract

Read online

Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.